ATE526029T1 - Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung - Google Patents
Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkungInfo
- Publication number
- ATE526029T1 ATE526029T1 AT02760663T AT02760663T ATE526029T1 AT E526029 T1 ATE526029 T1 AT E526029T1 AT 02760663 T AT02760663 T AT 02760663T AT 02760663 T AT02760663 T AT 02760663T AT E526029 T1 ATE526029 T1 AT E526029T1
- Authority
- AT
- Austria
- Prior art keywords
- histone deacetylase
- deacetylase inhibitor
- assessing
- medical use
- tumoral effect
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001250846 | 2001-08-21 | ||
| PCT/JP2002/008355 WO2003015810A1 (en) | 2001-08-21 | 2002-08-20 | Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE526029T1 true ATE526029T1 (de) | 2011-10-15 |
Family
ID=19079582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02760663T ATE526029T1 (de) | 2001-08-21 | 2002-08-20 | Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8470783B2 (de) |
| EP (1) | EP1426054B1 (de) |
| JP (1) | JP4238728B2 (de) |
| AT (1) | ATE526029T1 (de) |
| CA (1) | CA2457043A1 (de) |
| DK (1) | DK1426054T3 (de) |
| ES (1) | ES2371630T3 (de) |
| HU (1) | HU229521B1 (de) |
| MX (1) | MXPA04001612A (de) |
| NO (1) | NO331682B1 (de) |
| PL (1) | PL210794B1 (de) |
| PT (1) | PT1426054E (de) |
| RU (1) | RU2298414C2 (de) |
| WO (1) | WO2003015810A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005521737A (ja) * | 2002-04-05 | 2005-07-21 | 藤沢薬品工業株式会社 | 腎臓癌の治療のためのデプシペプチド |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2519320A1 (en) * | 2003-02-19 | 2004-09-02 | Astellas Pharma Inc. | Method of estimating antitumor effect of histone deacetylase inhibitor |
| JP2006520796A (ja) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
| EP1638541B1 (de) * | 2003-06-27 | 2010-05-19 | Astellas Pharma Inc. | Therapeutisches mittel für ein weichteilsarkom |
| EP2263694B1 (de) * | 2003-09-25 | 2013-06-12 | Astellas Pharma Inc. | Antitumormittel, enthaltend den Histon-deacetylase-inhibitor FK228 und den Topoisomerase-II-Inhibitor Doxorubicin |
| EP1713460A2 (de) * | 2003-12-10 | 2006-10-25 | Wisconsin Alumni Research Foundation | Fk228-analoga und ihre verwendung als hdac-hemmer |
| EP1697538A1 (de) * | 2003-12-18 | 2006-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Verfahren zur identifizierung von histondeacetylase-inhibitoren |
| US20050187148A1 (en) * | 2004-02-25 | 2005-08-25 | Yoshinori Naoe | Antitumor agent |
| KR101167601B1 (ko) * | 2004-02-25 | 2012-07-27 | 아스텔라스세이야쿠 가부시키가이샤 | 항종양제 |
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| JP2006000113A (ja) * | 2004-05-20 | 2006-01-05 | Masatomo Sakurai | 漢方医療の診断に用いる遺伝子およびその利用方法 |
| WO2006066133A2 (en) | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP2502649A1 (de) | 2005-02-03 | 2012-09-26 | TopoTarget UK Limited | Kombinationstherapie mit HDAC-Hemmern und Erlotinib zur Behandlung von Krebs |
| US7604939B2 (en) | 2005-03-01 | 2009-10-20 | The Regents Of The University Of Michigan | Methods of identifying active BRM expression-promoting HDAC inhibitors |
| US7642253B2 (en) | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| ATE542527T1 (de) | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| KR20080032188A (ko) | 2005-07-14 | 2008-04-14 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| US20080292616A1 (en) * | 2005-08-19 | 2008-11-27 | Government Of The United Of America, Represented By The Secretary, Department Of Health And.... | Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same |
| CA2627923C (en) | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| AU2006318652A1 (en) * | 2005-11-18 | 2007-05-31 | Gloucester Pharmaceuticals, Inc. | Metabolite derivatives of the HDAC inhibitor FK228 |
| CA2649877A1 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
| WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
| CA2674084C (en) | 2006-12-26 | 2013-05-14 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| JP2010514802A (ja) * | 2006-12-29 | 2010-05-06 | グラスター ファーマシューティカルズ， インコーポレイテッド | ロミデプシンをベースとする癌の処置 |
| JP2010514801A (ja) | 2006-12-29 | 2010-05-06 | グラスター ファーマシューティカルズ， インコーポレイテッド | ロミデプシンの精製 |
| AU2008210421B2 (en) | 2007-01-30 | 2014-03-13 | Pharmacyclics Llc | Methods for determining cancer resistance to histone deacetylase inhibitors |
| US8642809B2 (en) | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
| CA2804795A1 (en) * | 2010-07-12 | 2012-01-19 | Nicholas Vrolijk | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| RU2609833C2 (ru) | 2011-09-13 | 2017-02-06 | Фармасайкликс Элэлси | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
| US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
| AU732299B2 (en) | 1997-09-02 | 2001-04-12 | Japan Energy Corporation | Novel cyclic tetrapeptide derivatives and pharmaceutical use thereof |
| CA2308565A1 (en) * | 1997-11-05 | 1999-05-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
| JPH11335375A (ja) | 1998-05-20 | 1999-12-07 | Mitsui Chem Inc | ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体 |
| PL200861B1 (pl) | 1999-09-08 | 2009-02-27 | Sloan Kettering Inst Cancer | Pochodna kwasu suberynowego, jej zastosowanie i kompozycja farmaceutyczna |
| WO2001042282A1 (en) | 1999-12-08 | 2001-06-14 | Xcyte Therapies, Inc. | Depsipeptide and congeners thereof for use as immunosuppressants |
| CA2317003A1 (en) | 2000-02-28 | 2001-08-28 | Hidenori Nakajima | Gene expression potentiator |
| JP2001348340A (ja) * | 2000-06-07 | 2001-12-18 | Yamanouchi Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害剤 |
| ATE425177T1 (de) | 2000-07-17 | 2009-03-15 | Astellas Pharma Inc | Reduziertes fk228 und seine verwendung |
| JP2005521737A (ja) | 2002-04-05 | 2005-07-21 | 藤沢薬品工業株式会社 | 腎臓癌の治療のためのデプシペプチド |
| EP1638541B1 (de) | 2003-06-27 | 2010-05-19 | Astellas Pharma Inc. | Therapeutisches mittel für ein weichteilsarkom |
| EP2263694B1 (de) | 2003-09-25 | 2013-06-12 | Astellas Pharma Inc. | Antitumormittel, enthaltend den Histon-deacetylase-inhibitor FK228 und den Topoisomerase-II-Inhibitor Doxorubicin |
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
-
2002
- 2002-08-20 EP EP02760663A patent/EP1426054B1/de not_active Expired - Lifetime
- 2002-08-20 CA CA002457043A patent/CA2457043A1/en not_active Abandoned
- 2002-08-20 MX MXPA04001612A patent/MXPA04001612A/es active IP Right Grant
- 2002-08-20 PT PT02760663T patent/PT1426054E/pt unknown
- 2002-08-20 PL PL368708A patent/PL210794B1/pl unknown
- 2002-08-20 WO PCT/JP2002/008355 patent/WO2003015810A1/ja not_active Ceased
- 2002-08-20 JP JP2003520768A patent/JP4238728B2/ja not_active Expired - Lifetime
- 2002-08-20 DK DK02760663.1T patent/DK1426054T3/da active
- 2002-08-20 RU RU2004108137/15A patent/RU2298414C2/ru not_active IP Right Cessation
- 2002-08-20 ES ES02760663T patent/ES2371630T3/es not_active Expired - Lifetime
- 2002-08-20 HU HU0400668A patent/HU229521B1/hu not_active IP Right Cessation
- 2002-08-20 US US10/486,833 patent/US8470783B2/en not_active Expired - Lifetime
- 2002-08-20 AT AT02760663T patent/ATE526029T1/de active
-
2004
- 2004-02-20 NO NO20040731A patent/NO331682B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0400668A2 (hu) | 2005-01-28 |
| DK1426054T3 (da) | 2011-12-12 |
| MXPA04001612A (es) | 2004-07-08 |
| PL368708A1 (en) | 2005-04-04 |
| EP1426054A1 (de) | 2004-06-09 |
| ES2371630T3 (es) | 2012-01-05 |
| PL210794B1 (pl) | 2012-03-30 |
| EP1426054B1 (de) | 2011-09-28 |
| US8470783B2 (en) | 2013-06-25 |
| NO20040731L (no) | 2004-04-20 |
| HUP0400668A3 (en) | 2012-09-28 |
| CA2457043A1 (en) | 2003-02-27 |
| JP4238728B2 (ja) | 2009-03-18 |
| PT1426054E (pt) | 2011-12-06 |
| NO331682B1 (no) | 2012-02-20 |
| US20050191713A1 (en) | 2005-09-01 |
| JPWO2003015810A1 (ja) | 2004-12-02 |
| HU229521B1 (hu) | 2014-01-28 |
| RU2298414C2 (ru) | 2007-05-10 |
| RU2004108137A (ru) | 2005-05-10 |
| WO2003015810A1 (en) | 2003-02-27 |
| EP1426054A4 (de) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE526029T1 (de) | Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung | |
| ATE511655T1 (de) | Verfahren zur auswertung eines myelounterdrückungszustands | |
| ATE442592T1 (de) | Detektion und/oder beobachtung von synuclein- assoziierten krankheiten | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| NZ593388A (en) | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway | |
| ATE290375T1 (de) | Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen | |
| SV2002000245A (es) | Oxazolidinonas substituidas y su uso ref. lea 34122-sv | |
| ATE435015T1 (de) | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer | |
| TW200735890A (en) | Compositions and methods for increasing insulin sensitivity | |
| BR9916785A (pt) | Tratamento de asma com inibidores mek | |
| EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| ATE556711T1 (de) | Verfahren zur verbesserung der hautqualität | |
| BRPI0810336A2 (pt) | "método para tratar e/ou prevenir úlceras de pele em um indivíduo" | |
| BRPI0508451A (pt) | método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica | |
| CA2366682A1 (en) | Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker | |
| CY1108540T1 (el) | Ταυτοποιηση θεραπευτικων ενωσεων | |
| WO2007100728A3 (en) | Mannose derivatives for killing tumor cells | |
| ATE487484T1 (de) | Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür | |
| ATE557087T1 (de) | Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz | |
| ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| DE60140864D1 (de) | Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1426054 Country of ref document: EP |